About this trial
Severe pneumonia(SP) is a one of the main causes of death for critically ill patients.Samples of bronchoalveolar lavage fluid (BALF) from SP patients often report positive for herpes simplex virus type 1 (HSV-1) DNA. However, to date, it is unclear the impact and significance of this positive result on SP patients. This study will evaluate the prognostic impact of lower respiratory tract HSV-1 infection/reactivation on ICU severe pneumonia patients.At the same time, by analyzing the risk factors that affect prognosis, we will identify populations with the potential for intervention benefits and provide a basis for further intervention treatment.
Eligibility criteria
Qualifiers
1: Age>18 years old. 2: Clinical diagnosis for severe pneumonia. 3: ICU stay time >72 hours. 4: A written informed consent form was obtained from the members of the patients' family.
Disqualifiers
1: severe ventilation dysfunction, and effective respiratory support has not been used; 2: Aortic aneurysm and esophageal varices at risk of rupture; 3: Recent acute coronary syndrome, uncontrolled severe hypertension, and malignant arrhythmia; 4: Irreversible bleeding tendencies, such as severe coagulation dysfunction, massive hemoptysis, or gastrointestinal bleeding; 5: Multiple pulmonary bullae at risk of rupture. 6: Estimated survival time<24 hours. 7: Included in another interventional clinical study.
Trial design
Treatments tested in this trial
- Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy
- throat Swab
Treatment groups
Locations
Sponsors and collaborators
Second Affiliated Hospital of Guangzhou Medical University
Lead sponsor
Guangzhou Red Cross Hospital
Collaborator
Guangzhou First People's Hospital
Collaborator
Gongguan People's Hospital
Collaborator
Guangzhou Medical University
Collaborator